Monoclonal antibodies (mAbs) targeting CXCR4 have shown promising results in both solid tumors and hematological malignancies by blocking the CXCR4/CXCL12 axis and inducing cancer apoptosis. Here, CXCR4 is linked to hematologic disorder.